EX-10.23
from 10-K
7 pages
As We Have Discussed, Your Employment With Neogenomics, Inc. (The “Company”) Is Coming to an End, Effective as of December 31, 2022, (The “Separation Date”). the Purpose of This Letter Agreement (This “Agreement”) Is to Confirm the Terms Concerning Your Transition From Employment. Capitalized Terms Not Defined in This Agreement Will Have the Respective Meanings Ascribed to Them in the Employment Agreement by and Between You and the Company, Dated as of February 22, 2022 (The “Employment Agreement”)
12/34/56
EX-10.2
from 10-Q
2 pages
2.additional Compensation. Following the Transition Date, You Will Be Eligible to Receive Additional Compensation in the Form of a Bonus in Respect of Your Role as Executive Chair and Principal Executive Officer of the Company, in an Amount to Be Determined by the Culture and Compensation Committee of the Board. It Is Expected That the Amount of Such Additional Compensation, if Awarded, Would Be Between $500,000 and $2,000,000. Any Such Additional Compensation Will Be Paid to You Within Thirty (30) Days Following the Transition Date. 3. Benefits; Expense Reimbursement. (A)in Respect of Your Role as Executive Chair and Principal Executive Officer of the Company, You Shall Not Be Eligible to Participate in Any Employee Benefits Programs Maintained by the Company From Time to Time for Its Employees. (B)in Accordance With the Company’s Policies and Procedures, You Will Be Entitled to Reimbursement of All Reasonable and Properly Documented Expenses Incurred by You in the Performance of Your Duties Under This Agreement That Are Approved by the Company
12/34/56
